Gland Pharma Limited — Updates, 03-02-2025: Press Release

Gland Pharma Limited's financial results for Q3 FY25 reveal a revenue of ₹13,841 Mn, down 10% YoY but only 2% below the previous quarter. EBITDA increased by 1% YoY to ₹3,600 Mn, with an impressive EBITDA margin of 26%, up from 23% YoY. PAT grew by 7% YoY to ₹2,047 Mn, achieving a PAT margin of 15%. The highlights include a significant improvement in the base business's EBITDA margin, reaching 39%, and successful completion of USFDA inspections at key facilities.

On the operational front, the company launched 13 new molecules during the quarter and filed four ANDAs, with eight approvals received. Gland Pharma's strategic biologics CDMO collaborations are set to generate additional revenue starting next fiscal year, marking a positive outlook for future growth.

Looking at regional performance, the US market saw a decrease of 11% YoY, while revenues in Europe dropped 19%, and India recorded a 26% decline. However, Canada, Australia, and New Zealand exhibited a solid 20% growth. Overall, Gland Pharma is positioned for ongoing operational enhancement and strategic development.